Skip to main content

Day: August 17, 2024

UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Following recent transactions and cost-cutting efforts, Sol-Gel’s cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by the second quarter of 2026 SGT-210 proof-of-concept study in patients suffering from Darier disease, a significant unmet medical need in dermatology, is ongoing Sol-Gel sells its rights in the Abbreviated New Drug Application (ANDA) drug product generic to Zoryve® Cream (roflumilast cream 0.3%) Following management realignment, Mr. Mori Arkin, the Company’s executive chairman and controlling shareholder to be appointed as Company’s interim CEO as of January 1, 2025, subject to shareholders approval Sol-Gel recently signed license agreements with respect to TWYNEO and EPSOLAY...

Continue reading

Acceleware Ltd. Reports Second Quarter 2024 Financial and Operating Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, Aug. 17, 2024 (GLOBE NEWSWIRE) — Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of transformative technologies targeting the decarbonization of industrial process heat, today announced its financial and operating results for the six months ended June 30, 2024 (all figures are in Canadian dollars unless otherwise noted). Acceleware’s results reflect contributions from the Company’s two business units, radio frequency (“RF”) heating for industrial applications using the Company’s proprietary Clean Tech Inverter (“CTI”) including enhanced oil recovery (“RF XL”), and high-performance computing (“HPC”) scientific software. This news release should be read in conjunction with the Company’s unaudited interim condensed financial statements and the accompanying notes for the six...

Continue reading

Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global Stakeholders

Written by Customer Service on . Posted in Public Companies.

COPENHAGEN, Denmark, August 17, 2024 – Bavarian Nordic A/S (OMX: BAVA) provides an update on plans for securing supply of vaccines to tackle the current mpox outbreak that the Africa Centers for Disease Control and Prevention (Africa CDC) declared as a Public Health Emergency of Continental Security (PHECS) on August 13, 2024 followed by the World Health Organization (WHO) that declared mpox as a Public Health Emergency of International Concern (PHEIC) on August 14, 2024. “Bavarian Nordic is working closely with all stakeholders to ensure the equitable access to our mpox vaccine during the current PHECS and PHEIC. Importantly, we have built a strong partnership with the Africa CDC, both on supply, but also expanding our manufacturing network to include Africa. We are also working with the WHO on a regulatory path to ensure access to all...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.